Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Nursing | Ophthalmology | Pathology | Journal

Back to Journal Articles

Corneal Cell Transplant Can Restore Corneal Transparency

Last Updated: June 15, 2012.

 

Recovery seen in mice, primates after transplant of corneal cells plus selective ROCK inhibitor

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
When given together with the selective Rho-associated kinase inhibitor Y-27632, transplanted corneal endothelial cells can effectively treat damaged corneas in both rabbits and monkeys, according to an experimental study published online June 13 in The American Journal of Pathology.

FRIDAY, June 15 (HealthDay News) -- When given together with the selective Rho-associated kinase (ROCK) inhibitor Y-27632, transplanted corneal endothelial cells (CECs) can effectively treat damaged corneas in both rabbits and monkeys, according to an experimental study published online June 13 in The American Journal of Pathology.

Building on previous results showing that adhesion of CECs can be improved by the selective ROCK inhibitor Y-27632, Naoki Okumura, from the Kyoto Prefectural University of Medicine in Japan, and colleagues transplanted cultured CECs with Y-27632 into the eyes of rabbits and monkeys with corneal endothelial dysfunction.

The researchers found that, in rabbits, the corneas became completely transparent with 48 hours, but only when Y-27632 was injected with the CECs. There were no complications associated with the injection. Cell injection therapy-related complications, including abnormal deposition of the injected cells and increase in intraocular pressure, were not seen. The reconstructed corneal endothelium had a normal monolayer of hexagonally-shaped cells and had normal expression of markers related to function. Similar results were observed in monkeys, where transplantation of CECs with Y-27632 led to corneal transparency and a monolayer of hexagonal cells.

"This novel strategy of using a cell-based therapy combined with a ROCK inhibitor may ultimately provide clinicians with a new therapeutic modality in regenerative medicine, not only for the treatment of corneal endothelial dysfunctions but also for a variety of pathological diseases," Okumura and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Human Perivascular Stem Cells Superior for Bone Formation Next: Factors ID'd in Healing Failure of Diabetic Foot Ulcers

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.